
51 - 200 employees
Founded 2011
🧬 Biotechnology
💊 Pharmaceuticals
💰 $54.9M Series C - Numab on 2025-01
Biotechnology • Pharmaceuticals
Numab Therapeutics AG is a Swiss biotechnology company based in Horgen that discovers and develops next-generation multispecific antibody-based therapeutics for immunology and immuno-oncology. Numab uses proprietary discovery and engineering platforms (λ-Cap™ and MATCH™) to design plug-and-play multispecific molecules intended to improve potency, stability, pharmacokinetics, duration of effect, and safety versus first-generation antibodies. The company advances an in-house pipeline and collaborates with pharmaceutical partners (e. g. , Boehringer Ingelheim, Kaken Pharmaceutical) to co-develop and license multispecific antibody candidates for diseases including inflammatory bowel disease and retinal and tumor indications.
Selected: 🇬🇧 United Kingdom – Remote (UK).
Selected: 🆕 Date Added.
🕒 6 days ago
Senior Study Manager leading outsourced Phase I IBD study delivery for Numab, a Swiss biotech developing multispecific antibody immunotherapies. Coordinating CROs, sites, vendors and clinical systems.
🌐 Switzerland, United Kingdom – Remote
💰 $54.9M Series C - Numab on 2025-01
⏰ Full Time
🟠 Senior
👔 Manager
👻 Ghost score 12%